Φορτώνει......

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models

As key molecules which drive progression and chemoresistance in gastrointestinal cancers, EGFR and HER2 have become efficacious drug targets in this setting. Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. Histone deacetylase inhib...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: LaBonte, Melissa J., Wilson, Peter M., Fazzone, Will, Russell, Jared, Louie, Stan G., El-Khoueiry, Anthony, Lenz, Heinz-Josef, Ladner, Robert D.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2011
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3118510/
https://ncbi.nlm.nih.gov/pubmed/21464044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-2430
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!